Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.

Adding linagliptin to glimepiride treatment reduces some measures of glycemic variability and improves glycemic control in patients with HNF1A-MODY, indicate findings from the GLIMLINA trial.

Kohler S et al. Diabetes Care 2018: dc171525. doi: 10.2337/dc17-1525

This was recorded in 10.6% of patients treated with sitagliptin, 12.4% treated with glimepiride, 12.0% with liraglutide, and 11.9% with insulin glargine.

LEAD-2: Published Trial population: People with type 2 diabetes taking one or more oral antidiabetic medications Comparator treatments: Glimepiride, placebo NCT00318461 In this trial, published in Diabetes Care , people taking the highest liraglutide dose of 1.8 mg achieved an average 1.0% reduction in HbA1 during 26 weeks of treatment, as did those taking glimepiride.

Both doses of dulaglutide were significantly superior to glimepiride.

Deborah Wexler discusses the findings from GRADE, a head-to-head study comparing glimepiride, sitagliptin, insulin glargine, and liraglutide when used in combination with metformin for the treatment of type 2 diabetes.

Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.

The incidence ranged from 4.38 to 6.32 per 1000 person–years among those on glimepiride, gliclazide, or glipizide.

The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.

The top-line results of the CAROLINA trial indicate that linagliptin is non-inferior to glimepiride.

CAROLINA was a randomized controlled trial, whereas the current study is a retrospective analysis of data from 24,679 metformin users and 24,799 sulfonylurea users (glyburide, glipizide, or glimepiride).